HDAMM-predictor: prediction of progression in asymptomatic myeloma patients

Abstract

The HDAMM-predictor is based on microarray gene expression and predicts the risk of progression from asymptomatic to symptomatic myeloma. It divides the patients in three groups, from low to high risk to progress. It was generated according to the method published by Rème et al. 2013. Gene expression profiles of 259 asymptomatic myeloma patients were used as trainingset